Hims vs Noom Med: Which GLP-1 Provider Is Better?
By Iacob Pastina, Independent Researcher
Hims beats Noom Med overall, scoring 7.9/10 vs 7.4/10. Noom Med is more affordable at $99/mo vs $199/mo. Choose Hims for men who want a well-known publicly-traded brand and fda-appr. Choose Noom Med for users who want a tiered entry into glp-1 care — from $99/mo .
A side-by-side comparison of Hims and Noom Med covering pricing, scores, medication types, insurance, and more to help you decide.
Hims
#12 of 48The household name in men's telehealth, publicly traded as Hims & Hers Health (NYSE: HIMS). In 2026 Hims added FDA-approved brand-name Wegovy (injection and pill) and Ozempic through a direct Novo Nordisk partnership — alongside their existing compounded semaglutide program. Brand recognition and product breadth are real strengths. The trade-off: Hims' verified Trustpilot rating is 3.0 stars across 8,286 reviews (May 2026) — significantly below smaller competitors like Henry Meds (4.5) or Eden Health (4.5). The 1-star pool is 28% — the highest 1-star rate in our table — clustered around subscription/billing complaints.
Visit HimsNoom Med
#28 of 48Noom restructured Noom Med in 2026 into 3 tiers: $69/mo branded telehealth (med out-of-pocket), $99-149/mo Microdose GLP-1Rx (low-dose + biomarker monitoring), and the Full GLP-1Rx program ($149 intro → $349/mo on 12-week subscription). Coaching app included at every tier.
Visit Noom Med| Feature | Hims | Noom Med |
|---|---|---|
| Our Score | 7.9/10 | 7.4/10 |
| Starting Price | $199/mo | $99/mo |
| Medication Type | Both | Both |
| Insurance Accepted | No | Yes |
| Best For | Men who want a well-known publicly-traded brand and FDA-approved Wegovy through the 2026 Novo Nordisk partnership — but should know going in that Hims' customer-experience signal is weaker than smaller competitors | Users who want a tiered entry into GLP-1 care — from $99/mo Microdose all-in (low-dose + biomarkers + coaching) up to a full $349/mo medication + coaching program |
| Ranking | #12 | #28 |
Pros & Cons Compared
Hims
Pros
- +Publicly traded company (NYSE: HIMS) — SEC-filed financials, regulatory accountability that private competitors don't have.
- +2026 Novo Nordisk partnership — FDA-approved Wegovy injection, Wegovy pill, and Ozempic now available directly through Hims. Real brand-name access from a single platform.
- +$199/mo all-inclusive for compounded semaglutide, including consultations and shipping.
- +Polished app and web experience — among the best user interfaces in men's telehealth.
- +8,286 verified Trustpilot reviews is the second-largest review volume in our table (after Henry's 12,461) — significant real-world adoption.
Cons
- −Trustpilot rating is 3.0 stars / 8,286 reviews (May 2026) — significantly below Henry Meds (4.5), Eden Health (4.5), Yucca Health (4.6), MEDVi (4.4). The lowest customer-experience signal of any major brand we track.
- −28% of Trustpilot reviews are 1-star — the highest 1-star rate in our table. Top complaint themes: subscription handling, unexpected charges, customer service responsiveness.
- −Hims reviews span ALL their products (ED, hair loss, mental health, weight loss) — not just GLP-1. But the rating still applies because most users don't separate experiences by product.
- −'Hims Oral Kit' is NOT a GLP-1 — it's a non-GLP-1 metabolic combination (metformin + bupropion + topiramate + B12 + naltrexone). Easy to confuse with their compounded semaglutide. Read the product page carefully before signing up.
- −Brand Wegovy at $599/mo is not competitive with LillyDirect/NovoCare cash prices or with Hers ($149/mo for the same product via the same Novo partnership).
- −Generic high-volume support — large patient base means less personalized attention than smaller competitors.
Noom Med
Pros
- +Tiered 2026 entry — $69/mo branded telehealth tier lets users start with just medication access and the coaching app
- +New Microdose GLP-1Rx program ($99-149/mo) — low-dose GLP-1 + biomarker monitoring for sensitive users
- +Insurance accepted for qualifying plans — can significantly reduce out-of-pocket costs on brand-name meds
- +Industry-leading behavioral coaching app with years of psychology-based weight loss methodology
Cons
- −Tiered pricing creates confusion — $69, $99-149, or $149-349 depending on tier
- −Full GLP-1Rx program requires 12-week subscription ($149 intro rate applies only for the first few weeks)
- −Medication costs on the $69 tier are out-of-pocket — the low tier price is just the platform
- −App coaching still requires real engagement — skip-prone users waste the behavioral value
Our Verdict
Hims edges out Noom Med with a score of 7.9/10 vs 7.4/10. If budget is your priority, Noom Med starts at $99/mo compared to Hims's $199/mo. Noom Med accepts insurance, which can significantly reduce your out-of-pocket costs. Choose Hims if you want: men who want a well-known publicly-traded brand and fda-approved wegovy through the 2026 novo nordisk partnership — but should know going in that hims' customer-experience signal is weaker than smaller competitors. Choose Noom Med if you want: users who want a tiered entry into glp-1 care — from $99/mo microdose all-in (low-dose + biomarkers + coaching) up to a full $349/mo medication + coaching program.
Still undecided? Editor's #1 Overall Pick
Embody
$299/mo · 7.3/10 · Compounded
If neither Hims nor Noom Med feels like the right fit, our overall #1 pick across all 48 GLP-1 telehealth providers is Embody — strongest balance of clinical oversight, transparent pricing, and verified availability.
Read Full Reviews
Related comparisons
Other matchups readers comparing Hims or Noom Med tend to look at next.
- Hims vs Hers$199/mo
- Hims vs Shed$199/mo
- Hims vs Henry Meds$199/mo
- Noom Med vs Sprout Health$249/mo
- Noom Med vs Enhance MD$212/mo
- Noom Med vs Fridays$249/mo